1. Asparaginase pharmacology: challenges still to be faced

   • Claudia Lanvers-Kaminsky

   Review Article 14 February 2017 Pages: 439 - 450

   

2. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives

   • Archana Bhaw-Luximon
   • Dhanjay Jhurry

   Review Article 16 February 2017 Pages: 451 - 466

   

3. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting

   • Joseph V. Pergolizzi Jr.
   • Robert Taylor
   • Robert B. Raffa

   Review Article 24 February 2017 Pages: 467 - 477

   

4. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer

   • Jing Zhang
   • Jinyu Liu
   • Li Li

   Original Article 08 February 2017 Pages: 479 - 487

   

5. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

   • Toshio Shimizu
   • Kimio Yonesaka
   • Kazuhiko Nakagawa

   Original Article Open access 31 January 2017 Pages: 489 - 495

   

6. Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

   • Hisao Imai
   • Tomohito Kuwako
   • Masanobu Yamada

   Original Article Open access 06 February 2017 Pages: 497 - 505

   

7. Absorption, metabolism, and excretion of [¹⁴C]ponatinib after a single oral dose in humans

   • Yihua E. Ye
   • Caroline N. Woodward
   • Narayana I. Narasimhan

   Original Article Open access 09 February 2017 Pages: 507 - 518

   

8. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial

   • Junichi Koike
   • Kimihiko Funahashi
   • Shingo Kameoka

   Original Article 01 February 2017 Pages: 519 - 525

   

9. Effect of food on the bioavailability of palbociclib

   • Ana Ruiz-Garcia
   • Anna Plotka
   • Diane D. Wang

   Original Article 15 February 2017 Pages: 527 - 533

   

10. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

    • Zhan Wang
    • Juan Chen
    • Wei-Bing Zhou

    Original Article 27 February 2017 Pages: 535 - 543

    

11. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor

    • Melanie I. Titze
    • Otmar Schaaf
    • Thorsten Lehr

    Original Article 27 February 2017 Pages: 545 - 558

    

12. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

    • Peter N. Morcos
    • Katrijn Bogman
    • Bogdana Balas

    Original Article 27 February 2017 Pages: 559 - 568

    

13. NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis

    • Toshihiko Doi
    • Tetsuya Hamaguchi
    • Atsushi Ohtsu

    Original Article Open access 21 February 2017 Pages: 569 - 578

    

14. Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

    • Hidekazu Kuramochi
    • Masayuki Ando
    • Kazuhiko Hayashi

    Original Article 17 February 2017 Pages: 579 - 585

    

15. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer

    • Rajendar K. Mittapalli
    • Silpa Nuthalapati
    • Hao Xiong

    Original Article 28 February 2017 Pages: 587 - 594

    

16. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy

    • Akiyoshi Kasuga
    • Yasuo Hamamoto
    • Takanori Kanai

    Original Article 25 February 2017 Pages: 595 - 602

    

17. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma

    • Jennifer L. Clarke
    • Annette M. Molinaro
    • Michael D. Prados

    Clinical Trial Report 23 February 2017 Pages: 603 - 610

    

18. Phase I study of pazopanib plus TH-302 in advanced solid tumors

    • Richard F. Riedel
    • Kellen L. Meadows
    • Herbert I. Hurwitz

    Clinical Trial Report 25 February 2017 Pages: 611 - 619

    

19. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats

    • María Isabel Mas-Fuster
    • Amelia Ramon-Lopez
    • Ricardo Nalda-Molina

    Short Communication 06 February 2017 Pages: 621 - 627

    

20. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia

    • Yoshitaka Nishikawa
    • Taro Funakoshi
    • Manabu Muto

    Short Communication 15 February 2017 Pages: 629 - 633

    

21. Reply to: comment on “Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer”

    • Xiangzhen Kong

    Letter to the Editor 22 February 2017 Pages: 635 - 635